Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study.


Journal

Biomedical engineering online
ISSN: 1475-925X
Titre abrégé: Biomed Eng Online
Pays: England
ID NLM: 101147518

Informations de publication

Date de publication:
08 Sep 2021
Historique:
received: 08 06 2021
accepted: 28 08 2021
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

Ataxic gait is one of the most common and disabling symptoms in people with degenerative cerebellar ataxia. Intensive and well-coordinated inpatient rehabilitation improves ataxic gait. In addition to therapist-assisted gait training, robot-assisted gait training has been used for several neurological disorders; however, only a small number of trials have been conducted for degenerative cerebellar ataxia. We aimed to validate the rehabilitative effects of a wearable "curara®" robot developed in a single-arm study of people with degenerative cerebellar ataxia. Twenty participants with spinocerebellar ataxia or multiple system atrophy with predominant cerebellar ataxia were enrolled. The clinical trial duration was 15 days. We used a curara® type 4 wearable robot for gait training. We measured the following items at days 0, 7, and 14: Scale for the Assessment and Rating of Ataxia, 10-m walking time (10 mWT), 6-min walking distance (6 mWD), and timed up and go test. Gait parameters (i.e., stride duration and length, standard deviation of stride duration and length, cadence, ratio of the stance and swing phases, minimum and maximum knee joint angles, and minimum and maximum hip joint angles) were obtained using a RehaGait®. On days 1-6 and 8-13, the participants were instructed to conduct gait training for 30 ± 5 min with curara®. We calculated the improvement rate as the difference of values between days 14 and 0 divided by the value on day 0. Differences in the gait parameters were analyzed using a generalized linear mixed model with Bonferroni's correction. Data from 18 participants were analyzed. The mean improvement rate of the 10 mWT and 6 mWD was 19.0% and 29.0%, respectively. All gait parameters, except the standard deviation of stride duration and length, improved on day 14. Two-week RAGT with curara® has rehabilitative effects on gait function comparable to those of therapist-assisted training. Although the long-term effects after a month of RAGT with curara® are unclear, curara® is an effective tool for gait training of people with degenerative ataxia. Trial registration jRCT, jRCTs032180164. Registered: 27 February 2019; retrospectively registered. https://jrct.niph.go.jp/en-latest-detail/jRCTs032180164 .

Sections du résumé

BACKGROUND BACKGROUND
Ataxic gait is one of the most common and disabling symptoms in people with degenerative cerebellar ataxia. Intensive and well-coordinated inpatient rehabilitation improves ataxic gait. In addition to therapist-assisted gait training, robot-assisted gait training has been used for several neurological disorders; however, only a small number of trials have been conducted for degenerative cerebellar ataxia. We aimed to validate the rehabilitative effects of a wearable "curara®" robot developed in a single-arm study of people with degenerative cerebellar ataxia.
METHODS METHODS
Twenty participants with spinocerebellar ataxia or multiple system atrophy with predominant cerebellar ataxia were enrolled. The clinical trial duration was 15 days. We used a curara® type 4 wearable robot for gait training. We measured the following items at days 0, 7, and 14: Scale for the Assessment and Rating of Ataxia, 10-m walking time (10 mWT), 6-min walking distance (6 mWD), and timed up and go test. Gait parameters (i.e., stride duration and length, standard deviation of stride duration and length, cadence, ratio of the stance and swing phases, minimum and maximum knee joint angles, and minimum and maximum hip joint angles) were obtained using a RehaGait®. On days 1-6 and 8-13, the participants were instructed to conduct gait training for 30 ± 5 min with curara®. We calculated the improvement rate as the difference of values between days 14 and 0 divided by the value on day 0. Differences in the gait parameters were analyzed using a generalized linear mixed model with Bonferroni's correction.
RESULTS RESULTS
Data from 18 participants were analyzed. The mean improvement rate of the 10 mWT and 6 mWD was 19.0% and 29.0%, respectively. All gait parameters, except the standard deviation of stride duration and length, improved on day 14.
CONCLUSIONS CONCLUSIONS
Two-week RAGT with curara® has rehabilitative effects on gait function comparable to those of therapist-assisted training. Although the long-term effects after a month of RAGT with curara® are unclear, curara® is an effective tool for gait training of people with degenerative ataxia. Trial registration jRCT, jRCTs032180164. Registered: 27 February 2019; retrospectively registered. https://jrct.niph.go.jp/en-latest-detail/jRCTs032180164 .

Identifiants

pubmed: 34496863
doi: 10.1186/s12938-021-00929-w
pii: 10.1186/s12938-021-00929-w
pmc: PMC8424896
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP17hk0102048-19hk0102048

Informations de copyright

© 2021. The Author(s).

Références

Neurology. 2009 Dec 1;73(22):1823-30
pubmed: 19864636
BMC Pediatr. 2017 Mar 2;17(1):64
pubmed: 28253887
Cerebellum. 2014 Apr;13(2):248-68
pubmed: 24222635
Neurorehabil Neural Repair. 2017 Jul;31(7):609-622
pubmed: 28595509
J Neuroeng Rehabil. 2019 Jul 29;16(1):99
pubmed: 31358017
Curr Opin Neurol. 2020 Feb;33(1):150-160
pubmed: 31789706
Behav Neurol. 2018 Feb 20;2018:2892065
pubmed: 29675114
Ann Phys Rehabil Med. 2019 Sep;62(5):303-312
pubmed: 31377382
Arch Phys Med Rehabil. 2015 Jun;96(6):1006-13
pubmed: 25668777
Gait Posture. 2018 Feb;60:154-163
pubmed: 29220753
Clin Rehabil. 2015 Feb;29(2):143-53
pubmed: 25082955
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Neurorehabil Neural Repair. 2012 Jun;26(5):515-22
pubmed: 22140200
Neurology. 2018 Mar 6;90(10):464-471
pubmed: 29440566
J Neuroeng Rehabil. 2017 Mar 23;14(1):24
pubmed: 28330471
J Neuroeng Rehabil. 2020 Feb 19;17(1):25
pubmed: 32075669
J Neuroeng Rehabil. 2018 Sep 19;15(1):84
pubmed: 30231916
IEEE Trans Neural Syst Rehabil Eng. 2018 May;26(5):1011-1016
pubmed: 29752236
J Stroke Cerebrovasc Dis. 2019 Sep;28(9):2421-2428
pubmed: 31307899

Auteurs

Akira Matsushima (A)

Department of Neurology, JA Nagano Koseiren Kakeyu-Misayama Rehabilitation Center Kakeyu Hospital, Ueda, Japan. matsuaki82@gmail.com.

Yoichi Maruyama (Y)

Department of Rehabilitation, JA Nagano Koseiren Kakeyu-Misayama Rehabilitation Center Kakeyu Hospital, Ueda, Japan.

Noriaki Mizukami (N)

Department of Information Technology, International Professional University of Technology in Tokyo, Tokyo, Japan.

Mikio Tetsuya (M)

AssistMotion Inc., Ueda, Japan.

Minoru Hashimoto (M)

AssistMotion Inc., Ueda, Japan.
Faculty of Textile Science and Technology, Shinshu University, Ueda, Japan.

Kunihiro Yoshida (K)

Department of Neurology, JA Nagano Koseiren Kakeyu-Misayama Rehabilitation Center Kakeyu Hospital, Ueda, Japan.
Division of Neurogenetics, Department of Brain Disease Research, Shinshu University School of Medicine, Matsumoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH